Loading market dashboard
Crescita Therapeutics Inc.
CRRTFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. ("Crescita").
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of the Company (the “Shares”) in exchange for cash consideration of $0.80 per Share (the “Consider.
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that holders of the issued and outstanding common shares (the “Shares”) of the Company (each a “Shareholder”) will be entitled to receive $0.80 per Share (subject to any applicable withholdings) (the “Consideration”) under its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsid.
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that it has obtained a final court order from the Ontario Superior Court of Justice (Commercial List) approving its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all of the issued and outstanding common s.
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that at its special meeting (the “Meeting”) of shareholders (the “Shareholders”) held in person earlier today, Shareholders voted overwhelmingly in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary.
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2026 (“Q1-2026”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting S.
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) announced today that it has filed and mailed the management information circular (the “Circular”) and related materials in connection with the special meeting (the “Meeting”) of its shareholders (the “Shareholders”) to be held on May 14, 2026 in person at 2805 Place Louis-R-Renaud, Laval, Québec. The Meeting has been called for Shareholders to consider and, if deemed advisable,.
LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025 (“Q4-2025” and “F2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued b.
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its affiliate (the “Purchaser”) pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration (the “Arrangement”). The target pu.
